← The Wire
VIRNasdaq
Vir Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1706431
VIR Biotechnology develops and seeks approval for novel therapeutic product candidates through extensive clinical studies
red 8-K · 90d
$1.45B
Market cap
$10.38
Last close
+3.5%
1D
+8.5%
5D
1.9M
Volume
Price · last 39 sessions+2.0%
May 4L $8.25 · H $10.38Jun 29
161
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KExecutive ChangeJun 10, 20268-KExecutive Change · Shareholder VoteMay 28, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 16, 2026DEF 14ADEF 14AApr 16, 20268-KExecutive ChangeApr 10, 20268-KExecutive ChangeMar 4, 2026SC 13D/ASC 13D/AMar 3, 20268-KCompany UpdateMar 2, 20268-KMaterial AgreementFeb 26, 2026424B5424B5Feb 26, 2026424B5424B5Feb 24, 202610-K10-KFeb 23, 20268-KMaterial Agreement · Results of OperationsFeb 23, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KMaterial Agreement · Company UpdateDec 16, 202510-Q10-QNov 5, 20258-KResults of OperationsNov 5, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KCompany UpdateJul 24, 20258-KShareholder VoteMay 29, 20258-KCompany UpdateMay 9, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 7, 2025DEFA14ADEFA14AApr 17, 2025DEF 14ADEF 14AApr 17, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 26, 20258-KExecutive ChangeJan 30, 20258-KReg FD Disclosure · Company UpdateJan 8, 202510-Q10-QNov 4, 20248-KResults of OperationsOct 31, 20248-KExecutive Change · Acquisition / DispositionSep 10, 202410-Q10-QAug 1, 20248-KResults of Operations · Exit / Disposal CostsAug 1, 20248-KMaterial AgreementAug 1, 20248-KCompany UpdateJun 26, 20248-KReg FD DisclosureJun 5, 20248-KShareholder VoteMay 29, 2024DEFA14ADEFA14AMay 14, 202410-Q10-QMay 3, 20248-KResults of OperationsMay 2, 2024DEFA14ADEFA14AApr 19, 2024DEF 14ADEF 14AApr 19, 20248-KExecutive Change · Company UpdateApr 18, 202410-K10-KFeb 26, 20248-KMaterial Agreement · Results of OperationsFeb 22, 20248-KExecutive ChangeFeb 20, 2024SC 13GSC 13GJan 24, 20248-KExit / Disposal CostsDec 13, 20238-KMaterial Agreement · Agreement TerminatedNov 3, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 2, 20238-KMaterial AgreementOct 3, 20238-KExecutive ChangeSep 20, 202310-Q10-QAug 4, 20238-KResults of OperationsAug 3, 20238-KResults of Operations · Company UpdateJul 20, 20238-KShareholder VoteMay 23, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AApr 7, 2023DEF 14ADEF 14AApr 7, 20238-KReg FD DisclosureMar 13, 20238-KBylaw AmendmentMar 8, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 23, 20238-KCompany UpdateFeb 22, 20238-KExecutive ChangeFeb 16, 20238-KMaterial AgreementFeb 13, 20238-KExecutive ChangeJan 25, 202310-Q10-QNov 3, 20228-KResults of OperationsNov 3, 20228-KCompany UpdateOct 4, 2022SC 13GSC 13GSep 8, 202210-Q10-QAug 9, 20228-KResults of OperationsAug 9, 20228-KCompany UpdateAug 4, 2022
Insider Activity
In the 90 days to Mar 23, 2026: 6 sold $1.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Sabatini BrentSVP, Chief Accounting Officer | Sell | 7,711 | $9.12 | $70K |
| Mar 2, 2026 | Sato Vicki LDirector | Sell | 21,800 | $9.50 | $207K |
| Mar 2, 2026 | Sato Vicki LDirector | Sell | 200 | $9.98 | $2K |
| Feb 25, 2026 | De Verneuil VaninaEVP, General Counsel, Corp Sec | Sell | 13,700 | $9.82 | $135K |
| Feb 25, 2026 | Eisner MarkEVP and Chief Medical Officer | Sell | 1,889 | $9.82 | $19K |
| Feb 24, 2026 | Sato Vicki LDirector | Sell | 42,177 | $9.75 | $411K |
| Feb 24, 2026 | De Backer MarianneChief Executive Officer | Sell | 14,762 | $9.53 | $141K |
| Feb 24, 2026 | De Verneuil VaninaEVP, General Counsel, Corp Sec | Sell | 3,117 | $9.53 | $30K |
| Feb 24, 2026 | O'Byrne JasonEVP & Chief Financial Officer | Sell | 1,634 | $9.53 | $16K |
| Feb 24, 2026 | Eisner MarkEVP and Chief Medical Officer | Sell | 1,616 | $9.53 | $15K |
| Feb 24, 2026 | Sabatini BrentSVP, Chief Accounting Officer | Sell | 1,430 | $9.53 | $14K |
| Feb 24, 2026 | Sato Vicki LDirector | Sell | 200 | $10.26 | $2K |
| Feb 23, 2026 | De Backer MarianneChief Executive Officer | Sell | 19,039 | $7.45 | $142K |
| Feb 23, 2026 | De Verneuil VaninaEVP, General Counsel, Corp Sec | Sell | 4,445 | $7.45 | $33K |
| Feb 23, 2026 | Eisner MarkEVP and Chief Medical Officer | Sell | 2,089 | $7.45 | $16K |
| Feb 23, 2026 | O'Byrne JasonEVP & Chief Financial Officer | Sell | 2,089 | $7.45 | $16K |
| Feb 23, 2026 | Sabatini BrentSVP, Chief Accounting Officer | Sell | 1,829 | $7.45 | $14K |
| Feb 13, 2026 | Sabatini BrentSVP, Chief Accounting Officer | Sell | 1,530 | $7.79 | $12K |
| Feb 2, 2026 | Sato Vicki LDirector | Sell | 22,000 | $7.71 | $170K |
| Jan 2, 2026 | Sato Vicki LDirector | Sell | 22,000 | $5.93 | $130K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance